Search Results
May 08, 2026, 05:08 ET Oblique Therapeutics today announced that Dr. Jan Lundberg has joined the company as Scientific Advisor
that contributed to Eli Lilly becoming what is today the world's highest valued pharmaceutical company.Under Dr. Lundberg's leadership, several GLP 1 based medicines were developed, including therapies within the same drug class as Ozempic. These treatments from Eli Lilly have today become dominant
More news about: Oblique Therapeutics AB
May 08, 2026, 05:01 ET Oblique Therapeutics today announced that Dr. Jan Lundberg has joined the company as Scientific Advisor
that contributed to Eli Lilly becoming what is today the world's highest valued pharmaceutical company.Under Dr. Lundberg's leadership, several GLP 1 based medicines were developed, including therapies within the same drug class as Ozempic. These treatments from Eli Lilly have today become dominant
More news about: Oblique Therapeutics AB
May 07, 2026, 16:00 ET Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
with a ≥3-step improvement in DRSS (13.7% with Zenkuda vs 0% with sham, p<0.0001).Zenkuda showed strong efficacy independent of GLP-1 receptor agonist use, supporting its profile in a real-world diabetic population.Zenkuda was well tolerated with no instances of intraocular
More news about: Kodiak Sciences Inc.
May 07, 2026, 13:00 ET Walmart Has 23.6% of U.S. Grocery Sales - But Costco Owns the AI Answer - 5W Grocery Retail AI Visibility Index 2026
ChatGPT and Claude weight Reddit heavily.The report also identifies six 2026 dynamics reshaping the category, including the new GLP-1 grocery basket, Aldi's expansion as a citation-compounding program, and Walmart's CEO transition from Doug McMillon to John Furner — effective February
More news about: 5W Public Relations
May 07, 2026, 12:28 ET DialCare Partners with TrestleTree to Deliver Holistic Health Solutions for Employers Nationwide
care needs. With convenient virtual access to trusted coaches, physicians and prescriptions for non-DEA controlled substances — including GLP-1 medications for weight management and improved metabolic health — employees gain the resources needed to drive lasting lifestyle changes."We're
More news about: DialCare
May 07, 2026, 10:31 ET Health and Wellness Product Market to Reach USD 18.5 Billion by 2036 as Personalized Nutrition, Functional Foods, and Smart Wellness Technologies Transform Preventative Healthcare | Future Market Insights
https://www.futuremarketinsights.com/reports/detox-drink-marketGLP-1 Hydration Products Market https://www.futuremarketinsights.com/reports/glp-1-hydration-products-marketAbout Future
More news about: Future Market Insights
May 07, 2026, 09:00 ET hol+ Buckhead, Brookhaven & Johns Creek: Atlanta's Only Physician-Led, Whole-Body GLP-1 & Peptide Therapy Program
using the best tools available, including GLP-1s and peptides, in the precise combination and sequence that works for their body."How hol+ Differs From Every Other GLP-1 & Peptide Clinic in AtlantaAtlanta's GLP-1 and peptide market has expanded rapidly
More news about: Hol+
May 07, 2026, 07:00 ET Wegovy® access expanded for Medicare beneficiaries living with obesity through the Medicare GLP-1 Bridge starting July 1, 2026
the Medicare GLP-1 Bridge expands patient access to authentic, FDA-approved Wegovy®PLAINSBORO, N.J., May 7, 2026 /PRNewswire/ -- The Medicare GLP-1 Bridge will provide
More news about: Novo Nordisk
May 06, 2026, 22:37 ET ACROBiosystems、Carterraと提携して潜在的な医薬品候補の大規模特性評価を加速
用上多くの制限が残っています。この問題の克服を狙い、ACROBiosystems社は「FLAG」技術プラットフォームを確立しました。この統合プラットフォームには、質の高いフルレングスの標的を開発する複数の革新的なアプローチを採用されています。このようなタンパク質は安定した構造と高い生物学的活性を示しており、ポートフォリオにはCD20、Claudin18.2/18.1/6/9、GPRC5D、CCR8、STEAP1/2/3/4、GLP-1R、GIPRといった主な標的が含まれます。これらは、作用機序の研究と創薬の円滑化と加速を目的として設計されています。これらの安定した貫
More news about: ACROBiosystems Inc. 株式会社アクロバイオシステムズ
May 06, 2026, 16:01 ET Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
(MDD), with results expected in Q1 2027.The Thetis Phase III study of NEREUS™ for the prevention of vomiting in patients receiving GLP-1 receptor agonist therapies, with results expected in 2026.The Phase III study of VQW-765 in the treatment of adults with social anxiety
More news about: Vanda Pharmaceuticals Inc.
May 06, 2026, 14:11 ET As AI Rewrites Drug Development, the Industry Gathers in Philadelphia to Work Out the Rules
other leading pharmaceutical companies. More than 150 sessions will take on the biggest questions facing the field, from AI governance and GLP-1 innovation to CAR-T access and global regulatory harmonization.Physician-scientist and Every Cure co-founder David Fajgenbaum delivers the
More news about: Drug Information Association
May 06, 2026, 13:23 ET Genova Premium Tuna Launches Mediterranean Tuna Bowls, New High-Protein Go-To
diet. Genova's Mediterranean Tuna Bowls are also perfectly portioned and feature protein and fiber, making them great for GLP-1 lifestyles.Where to Buy Genova Mediterranean Tuna BowlsVisit
More news about: Genova Premium Seafood
May 06, 2026, 13:13 ET Protein Is Everywhere - Here's What Consumers Are Getting Wrong
a daily priority for supporting muscle health and overall function.3. The Rise of GLP-1 Medications Is Changing How People EatAs the use of GLP-1 medications for weight loss continues to grow, more consumers are eating fewer calories overall, often
More news about: Nutrishop
May 06, 2026, 12:10 ET 19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities
Recently, BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as "BrightGene Bio-Medical " or "the Company") announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist, BGM0504 injection, has achieved positive topline
More news about: BrightGene
May 06, 2026, 09:03 ET Fitnescity Health Launches the Clinical Integrity Standard for DEXA Body Composition Testing
/PRNewswire/ -- DEXA body composition testing has quietly become one of the most consequential health decisions consumers make — informing GLP-1 treatment, sarcopenia screening, and long-term longevity planning. Yet most consumers may not know that a low-cost service may not deliver the reproducible
More news about: Fitnescity Health
May 06, 2026, 09:00 ET Propel Launches Clear Protein, a Refreshing New Take on Functional Hydration with 20g Protein, Fiber and Electrolytes
flavorful sip. It's now available via Walmart.com, Amazon, Gatorade.com and TikTok Shop.Developed with registered dietitians with GLP-1 users in mind, Propel Clear Protein fills consumer demand for refreshing protein options and multifunctional beverages that support active wellness
More news about: Propel
May 06, 2026, 09:00 ET Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
improve blood sugar (glucose). As the first and only FDA-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body's receptors for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is not known if Mounjaro is safe and effective
More news about: Eli Lilly and Company
May 06, 2026, 07:07 ET Amble Health Announces the Amble Cares Program - Expanding Access to Weight Loss Program Treatments for Low-Income Americans
Cares Program. The national initiative is designed to give low-income Americans access to weight loss program treatments, which may include a GLP-1 prescription if eligible, at up to 50% lower cost, bringing life-changing care within reach of the populations historically priced out of it.
More news about: Amble Health
May 05, 2026, 20:10 ET Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR
More news about: Ascletis Pharma Inc.
May 05, 2026, 20:10 ET 歌禮將攜多個項目數據亮相第33屆歐洲肥胖症大會（ECO 2026）
天，比替爾泊肽長6倍，在DIO小鼠模型中減重效果較替爾泊肽相對提升71% (ASC35, a Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist Peptide, Demonstrated 14-day Average Observed Half-life, 6-fold Longer than Tirzepatide, in NHP Model and 71% More Relative Weight
More news about: 歌禮製藥有限公司
May 05, 2026, 12:45 ET Tropical Smoothie Cafe® Introduces New Toasted Snack Rolls for the Perfect Smoothie Pairing
balanced mix of savory and sweet with a tangy finishAs guest preferences continue to evolve with wellness trends and the rise of GLP-1 usage, smaller snack-size options are becoming the norm. With pricing starting at $3.99 for one or $7.49 for two*, Toasted Snack Rolls are an easy,
More news about: Tropical Smoothie Cafe
May 05, 2026, 11:00 ET Calibrate Publishes Largest Real-World Four-Year Analysis of GLP-1 Weight Loss Outcomes When Paired with Integrated Behavioral Support
behavior-assisted obesity management: more than 50,000 members drawn from nearly six years of clinical data. The analysis shows Calibrate members on GLP-1s lose, on average, 16% of their body weight in the first year (N = 37,031), 18% by year two (N = 11,132), 20% by year three (N
More news about: Calibrate Health, Inc
May 05, 2026, 10:39 ET THE AESTHETIC SYNDICATE EVOLVES INTO MANOR, REDEFINING THE FUTURE OF AESTHETICS AND WELLNESS
Non-invasive and minimally invasive solutions for reshaping and refiningGLP-1 Weight Loss Therapy — Medically supervised weight loss programs utilizing the latest in GLP-1 medications, integrated within a broader wellness frameworkPeptides — Cutting-edge
More news about: MANOR
May 05, 2026, 10:30 ET GLP-1 Hydration Products Market Outlook 2036 with Key Contributions from Smoothie King, Liquid I.V., Electrolit, Abbott, Nestlé Health Science, and ADM | Future Market Insights
GLP-1 hydration products market is entering a rapid expansion phase as hydration becomes a critical support category for users of GLP-1-based therapies. Growth is being driven by evolving consumption patterns,
More news about: Future Market Insights
May 05, 2026, 10:00 ET COSRX Launches Blue Peptide Serum to Help Restore Skin Plumpness and Support Healthy Aging
Why Skin Plumpness Matters in the Era of GLP-1 TreatmentsAs skin naturally evolves over time, changes in firmness, elasticity, and volume are inevitable, driven by factors such as
More news about: COSRX